Gaviscon Peppermint Tablets Tablets  (8 Unit)

Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion. © 2017 Reckitt Benckiser Pharmaceuticals (Pty) Ltd. Gaviscon is a registered trademark of the RB Group. Consumer care line: 0861 11 11 00. Scheduling status: SO. Proprietary name (and dosage form): Gaviscon double action tablets (tablets). Composition: Each tablet contains: Sodium alginate - 250 mg. Sodium bicarbonate - 106.50 mg. Calcium carbonate - 187.50 mg. Pharmacological classification: A 11.10 Medicines acting on gastro-intestinal tract, special combinations. Pharmacological action: Alginate reacts with gastric acid to form a viscous gel, having a near neutral pH. Sodium bicarbonate and calcium carbonate have acid neutralising properties. The mode of action of the tablets is physical and does not depend on absorption into the systemic circulation. Indications: Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion. Identification: A flat circular, bi-layered tablet with bevelled edges, pink and slightly mottled with sword and circle on the obverse and white with "GDA250" on the reverse, and an odour and flavour of mint. Presentation: Cartons containing 8 and 24 tablets in blisters comprising of unprinted, glass-clear, thermoformable laminates of uPVC/PE/PVDC with aluminium foil lidding. Name and business adores of the holder of the certificate of registration: Reckitt Benckiser Pharmaceuticals (Pty) Ltd.